Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

This study has been completed.
Information provided by (Responsible Party):
Exelixis Identifier:
First received: February 12, 2010
Last updated: July 28, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)